Intellia Therapeutics, Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for NTLA, updated each market day.
NTLA AI Sentiment
AI sees no strong directional signal for Intellia Therapeutics, Inc stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Intellia Therapeutics, Inc
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Sector
Exchange
Market Cap
$1,633,786,941
Cap Tier
Employees
377
Headquarters
CAMBRIDGE, MA
Listed Since
May 6, 2016
Website
NTLA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
NTLA Volatility
Intellia Therapeutics, Inc has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
